Open access · Peer reviewed · No APCs
CorrespondenceJournal of Pharmacology and PharmacotherapeuticsVol. 2 | Issue 4 | 2011 | pp. 307–308Open access
Benfluorex withdrawal in France: Still be hiding somewhere in the world?
- 1,
- 1,
- 1,
- 1*
- 1 Christophe Leroyer Université Européenne de Bretagne, UBO, EA3878 (GETBO) [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Christophe Leroyer
Christophe Leroyer Université Européenne de Bretagne, UBO, EA3878 (GETBO) [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].
Email: christophe.leroyer@chu-brest.fr
Copyright: © 2011 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2011
How to cite
Frachon, I., Gal, G., Hill, C., & Leroyer, C. (2011). Benfluorex withdrawal in France: Still be hiding somewhere in the world? Journal of Pharmacology and Pharmacotherapeutics, 2(4), 307–308. https://doi.org/10.4103/0976-500X.85942
Abstract
Bhattacharyya et al. have recently reviewed the evidences demonstrating the association between the development of valvular heart disease and the use of appetite suppressants, including fenfl uramine.[1] Among numerous epidemiological data, evidence for a dose-effect relationship as well as demonstration of the underlying mechanism trough involvement of 5HT2B serotonin strongly argue for fenfl uramine exposure as a causal factor for valvular heart disease
Keywords
Subject
Article metadata
| Title | Benfluorex withdrawal in France: Still be hiding somewhere in the world? |
|---|---|
| Authors | Irène Frachon; Grégoire Gal; Catherine Hill; Christophe Leroyer |
| Affiliations | Christophe Leroyer Université Européenne de Bretagne, UBO, EA3878 (GETBO) [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78]. |
| Corresponding author | christophe.leroyer@chu-brest.fr |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 2, Issue 4 (2011) |
Also in this issue
- ACE inhibitor and angiotensin-receptor blocker – A deadly combinationpp. 311–312
- The National Formulary of India 2010: Thorough and extensive revision of the preprint version neededpp. 219–20
- Research publications: Should they be mandatory for promotions of medical teachers?pp. 221–222
- The curious case of zinc for diarrhea: Unavailable, unprescribed, and unusedpp. 225–226
- Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellituspp. 230–235
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026